Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.01
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $759029.00 · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3M
P/E
N/A
•EV/EBITDA
19.4x
↑ROE
4.7%
↑Gross Margin
29.6%
↓Debt/Equity
-3.83
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.6%
FCF CAGR
—
FCF margin
9.6%
FCF / Net income
-7.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $17.4M · net income $-217042.0 · FCF $1.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $17.4M | $17.4M | $19.4M | $16.9M | $12.5M |
| Net Income | $-217042.00 | $-217042.00 | $-1.1M | $-13.4M | $-17.8M |
| EBITDA | $1.0M | $1.0M | $313671.00 | $-10.6M | $-13.8M |
| EPS | — | — | — | -0.03 | -0.04 |
| Gross Margin | 29.6% | 29.6% | 15.2% | -8.1% | 21.5% |
| Operating Margin | 3.9% | 3.9% | -12.0% | -56.1% | -40.6% |
| Net Margin | -1.2% | -1.2% | -5.9% | -79.2% | -142.0% |
| Balance Sheet | |||||
| Debt/Equity | -3.83 | -3.83 | -4.75 | -4.76 | 2.07 |
| Current Ratio | 1.03 | 1.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.7M | $1.7M | $759029.00 | $-2.3M | $-5.1M |
| Returns | |||||
| ROE | 4.7% | 4.7% | 32.3% | 361.9% | -209.0% |
| Valuation | |||||
| EV/EBITDA | 19.40 | 19.40 | 67.28 | — | — |
| P/B | — | — | — | — | 1.32 |
| Growth & Yield | |||||
| Revenue Growth | -9.8% | -9.8% | 14.6% | 34.6% | — |
| EPS Growth | — | — | — | 25.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.0%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
-50.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.